tetano
Editor, Senior Moderator
Pediatr Allergy Immunol
. 2021 Dec 2.
doi: 10.1111/pai.13709. Online ahead of print.
Infection with SARS-CoV-2 among children with asthma: evidence from Global Asthma Network
Chen-Yuan Chiang[SUP] 1 2 [/SUP], Philippa Ellwood[SUP] 3 [/SUP], Eamon Ellwood[SUP] 3 [/SUP], Luis García-Marcos[SUP] 4 [/SUP], Refiloe Masekela[SUP] 5 [/SUP], Innes Asher[SUP] 3 [/SUP], Héctor Badellino[SUP] 6 [/SUP], Alberto Bercedo Sanz[SUP] 7 [/SUP], Konstantinos Douros[SUP] 8 [/SUP], Asma El Sony[SUP] 9 [/SUP], Carlos González Diaz[SUP] 10 [/SUP], Ms Albi Rodríguez[SUP] 11 [/SUP], Ana Moreno-Salvador[SUP] 12 [/SUP], Luis F Pérez-Martini[SUP] 13 [/SUP], Nelson Rosário Filho[SUP] 14 [/SUP], Andrei Shpakou[SUP] 15 [/SUP], Shairbek Sulaimanov[SUP] 16 [/SUP], Marzieh Tavakol[SUP] 17 [/SUP], José Valverde-Molina[SUP] 18 [/SUP], Abdullah A Yousef[SUP] 19 [/SUP], Neil Pearce[SUP] 20 [/SUP], GAN COVID Study Group
Affiliations
Abstract
Background: Clinical presentations of coronavirus disease 2019 (COVID-19) among children with asthma have rarely been investigated. This study aimed to assess clinical manifestations and outcome of COVID-19 among children with asthma, and whether the use of asthma medications was associated with outcomes of interest.
Methods: The Global Asthma Network (GAN) conducted a global survey among GAN centres. Data collection was between November 2020 and April 2021.
Results: Fourteen GAN centres from 10 countries provided data on 169 children with asthma infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 was asymptomatic in 58 (34.3%), mild in 93 (55.0%), moderate in 14 (8.3%) and severe/critical in 4 (2.4%). Thirty-eight (22.5%) patients had exacerbation of asthma and 21 (12.4%) were hospitalized for a median of 7 days (interquartile range 3-16). Those who had moderate or more severe COVID-19 were significantly more likely to have exacerbation of asthma as compared to those who were asymptomatic or had mild COVID-19 (adjusted odds ratio (adjOR) 3.97, 95% CI 1.23-12.84). Those who used inhaled bronchodilators were significantly more likely to have a change of asthma medications (adjOR 2.39, 95% CI 1.02-5.63) compared to those who did not. Children who used inhaled corticosteroids (ICS) did not differ from those who did not use ICS with regards to being symptomatic, severity of COVID-19, asthma exacerbation and hospitalization.
Conclusions: Over dependence on inhaled bronchodilator may be inappropriate. Use of ICS may be safe and should be continued in children with asthma during the pandemic of COVID-19.
Keywords: COVID-19; ICS; SARS-CoV-2; asthma; children; inhaled corticosteroid.
. 2021 Dec 2.
doi: 10.1111/pai.13709. Online ahead of print.
Infection with SARS-CoV-2 among children with asthma: evidence from Global Asthma Network
Chen-Yuan Chiang[SUP] 1 2 [/SUP], Philippa Ellwood[SUP] 3 [/SUP], Eamon Ellwood[SUP] 3 [/SUP], Luis García-Marcos[SUP] 4 [/SUP], Refiloe Masekela[SUP] 5 [/SUP], Innes Asher[SUP] 3 [/SUP], Héctor Badellino[SUP] 6 [/SUP], Alberto Bercedo Sanz[SUP] 7 [/SUP], Konstantinos Douros[SUP] 8 [/SUP], Asma El Sony[SUP] 9 [/SUP], Carlos González Diaz[SUP] 10 [/SUP], Ms Albi Rodríguez[SUP] 11 [/SUP], Ana Moreno-Salvador[SUP] 12 [/SUP], Luis F Pérez-Martini[SUP] 13 [/SUP], Nelson Rosário Filho[SUP] 14 [/SUP], Andrei Shpakou[SUP] 15 [/SUP], Shairbek Sulaimanov[SUP] 16 [/SUP], Marzieh Tavakol[SUP] 17 [/SUP], José Valverde-Molina[SUP] 18 [/SUP], Abdullah A Yousef[SUP] 19 [/SUP], Neil Pearce[SUP] 20 [/SUP], GAN COVID Study Group
Affiliations
- PMID: 34856034
- DOI: 10.1111/pai.13709
Abstract
Background: Clinical presentations of coronavirus disease 2019 (COVID-19) among children with asthma have rarely been investigated. This study aimed to assess clinical manifestations and outcome of COVID-19 among children with asthma, and whether the use of asthma medications was associated with outcomes of interest.
Methods: The Global Asthma Network (GAN) conducted a global survey among GAN centres. Data collection was between November 2020 and April 2021.
Results: Fourteen GAN centres from 10 countries provided data on 169 children with asthma infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 was asymptomatic in 58 (34.3%), mild in 93 (55.0%), moderate in 14 (8.3%) and severe/critical in 4 (2.4%). Thirty-eight (22.5%) patients had exacerbation of asthma and 21 (12.4%) were hospitalized for a median of 7 days (interquartile range 3-16). Those who had moderate or more severe COVID-19 were significantly more likely to have exacerbation of asthma as compared to those who were asymptomatic or had mild COVID-19 (adjusted odds ratio (adjOR) 3.97, 95% CI 1.23-12.84). Those who used inhaled bronchodilators were significantly more likely to have a change of asthma medications (adjOR 2.39, 95% CI 1.02-5.63) compared to those who did not. Children who used inhaled corticosteroids (ICS) did not differ from those who did not use ICS with regards to being symptomatic, severity of COVID-19, asthma exacerbation and hospitalization.
Conclusions: Over dependence on inhaled bronchodilator may be inappropriate. Use of ICS may be safe and should be continued in children with asthma during the pandemic of COVID-19.
Keywords: COVID-19; ICS; SARS-CoV-2; asthma; children; inhaled corticosteroid.